Curbside Consult Volume 17, Issue 1 - First Quarter 2019

Research Updates 

Association of Race/Ethnicity with Oral Anticoagulant Use in Patients with Atrial Fibrillation
Kristine Conrow, Pharm.D., Walgreens/UMP Bethesda Clinic
Atrial Fibrillation: Are all patients receiving equal treatment? 

VTE Risk with HRT
Rachel Wilhelm, Pharm.D., Minnesota Community Care
Hormone replacement therapy in menopause has been associated with increased risk of venous thromboembolism. Are certain doses or product formulations safer than others?

Examining the Correlation Between Antidepressant Target Dose Optimization and Achievement of Glycemic Control
Stephanie Walek, Pharm.D., Allina Health
Patients with comorbid diabetes and depression are at an increased risk for poor glycemic control. What influence does antidepressant dosing optimization have on reducing hemoglobin A1c (HbA1c) in this population? 

Therapeutic Thoughts

SGLT2 Inhibitors: Are We Throwing the Baby Out With the Bathwater
Crosby Tindal, Pharm.D., SUPERVALU
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are perhaps the most controversial class of oral antidiabetic medications. Several potentially adverse effects may deter their use, but emerging evidence continues to underscore robust, clinically-significant benefits conferred by these agents. 

Pharmacist Impact on Deprescribing in Older Adults
Michelle Tran, Pharm.D., Fairview Pharmacy Services
Potentially inappropriate medications, such as those on the Beers Criteria list, continue to be commonly used in older adults. Pharmacists are key players in the healthcare system who can lead the efforts in deprescribing medications in the older adult population.

Updates in COPD: The 2019 GOLD Guidelines
Sara Massey, Pharm.D., Smiley’s Family Medicine Clinic
Following the 2019 update to the GOLD guidelines, should your practice change? 

From the Pharmacy Press  

Polypharmacy Effects in Patients with Nonvalvular Atrial Fibrillation on Rivaroxaban or Warfarin
Kaity Bader, Pharm.D., Apple Valley Medical Clinic, Fairview Physician Associates
Does polypharmacy affect anticoagulant medications in nonvalvular atrial fibrillation?  Read on to learn about the safety and efficacy results for rivaroxaban versus warfarin in these patients. 

Initiation of Triple Therapy in Chronic Obstructive Pulmonary Disease
Stephanie Keller, Pharm.D., Coborn’s Pharmacy / CHI St. Gabriel’s Health Family Medical Center
A new study investigates U.S. prescribing patterns for the treatment of COPD.

Patients’ interpretation of responsibility with warfarin therapy
Rebekka Schrecengost, Pharm.D., Essentia Health
Are patients feeling the blame when INR values are not at goal? 

Miscellaneous News  

FDA takes steps to make naloxone OTC
Charlie Sieberg, Pharm.D., New Ulm Medical Center
Read more to find out how the FDA is paving the way for drug companies to produce OTC naloxone products.

FDA approves the return of OTC Primatene® Mist
Charlie Sieberg, Pharm.D., New Ulm Medical Center
With the approval of an OTC inhaler, is asthma now a "do-it-yourself" disease?"

Associations Between Initial Opioid Exposure and the Likelihood for Long-term Use
George Cullina, Pharm.D., Cashwise Clinic Pharmacy / ACMC
A new study has identified risk factors that are associated with higher risks of long-term opioid use. How has this information already impacted practice and what changes are possible in the future?

New Drug Update

Revefenacin (YupelriTM) - Theravance Biopharma and Mylan
George Cullina, Pharm.D., Cashwise Clinic Pharmacy / ACMC
The FDA recently approved YupelriTM, an anticholinergic agent,for the treatment of COPD. Does this medication have a place in the current therapy recommendations?